IASO Bio Announces U.S. FDA Approval of Investigational New Drug Application for BCMA CAR-T Equecabtagene Autoleucel for Generalized Myasthenia Gravis
- Written by PR Newswire
SHANGHAI and NANJING, CHINA, and SAN JOSE, Calif., April 5, 2024 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therapy and antibody products, is pleased to announce that the Investigational New Drug (IND) application for its BCMA...
